Maintaining remissions accross the lifespan: A roundtable with Crohn's disease experts

Inflammatory Bowel Diseases

Volumn 10, Issue 8 SUPPL. 2, 2004, Pages

  Lichtenstein, Gary R ^a   Cuffari, Carmen ^b   Kane, Sunanda V ^c   Hanauer, Stephen ^c   Present, Daniel H ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 1; LEUKOTRIENE; MESALAZINE; METHOTREXATE; OLSALAZINE; PHYTOHEMAGGLUTININ; PLACEBO; PREDNISONE; PROSTAGLANDIN; SALAZOSULFAPYRIDINE; THROMBOCYTE ACTIVATING FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ACNE; ALOPECIA; AMENORRHEA; ARTICLE; ASEPTIC NECROSIS; ATHEROSCLEROSIS; BRAIN PSEUDOTUMOR; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CROHN DISEASE; DEPRESSION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG MECHANISM; EDEMA; ENDOCRINE DISEASE; ENZYME INHIBITION; EOSINOPENIA; ESOPHAGITIS; EXOPHTHALMOS; EYE DISEASE; EYE INFECTION; FETUS DISEASE; FISTULA; GASTROINTESTINAL DISEASE; GLAUCOMA; GROWTH RETARDATION; GYNECOLOGIC DISEASE; HAIR DISEASE; HAIR LOSS; HEADACHE; HEMATOLOGIC DISEASE; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIC ALKALOSIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ILEUM RESECTION; IMMUNE DEFICIENCY; IMMUNOMODULATION; INTESTINE PERFORATION; INTRAOCULAR HEMORRHAGE; LEUKOCYTOSIS; LIFESPAN; LONG TERM CARE; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; METABOLIC DISORDER; MOOD DISORDER; MOON FACE; MUSCLE ATROPHY; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; NAUSEA; NEPHRITIS; OBESITY; OSTEOPOROSIS; PANCREATITIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PEPTIC ULCER; PERIPHERAL NEUROPATHY; PIGMENT DISORDER; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; PURPURA; QUALITY OF LIFE; REMISSION; SEIZURE; SKIN ATROPHY; SKIN BRUISING; SKIN DISEASE; SKIN INFECTION; SMOKING CESSATION; STRIA; SYMPTOMATOLOGY; TREATMENT PLANNING; VOMITING; ADULT; CHILD; HOSPITALIZATION; RECURRENT DISEASE;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CROHN DISEASE; HUMANS; MESALAMINE; PATIENT COMPLIANCE; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 3543062383     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200407002-00003     Document Type: Article

References (15)

1. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979;77:843-846.
2. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 2001;96:635-643.
3. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993;104:1293-1301.
4. Hanauer SB, Krawitt EL, Robinson M, et al. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am J Gastroenterol. 1993;88: 1343-1351.
5. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med. 1998;339:370-374.
6. Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroe. 1999;94:674-678.
7. Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1996;110:688-693.
8. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260.
9. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-362.
10. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77:847-869.
11. Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol. 2002;97:803-823.
12. Cuffari C, Bayless TM. Crohn's disease: influence of age at onset on clinical phenotype. Gastro Internat. 1997;10:89-98.
13. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465-1473.
14. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.
15. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114: 39-43.